Advances study of t(8;21) acute myeloid leukemia
10.3760/cma.j.issn.1009-9921.2010.06.024
- VernacularTitle:伴有t(8;21)的急性髓系白血病研究进展
- Author:
Huamin SHAO
;
Qun SHEN
- Publication Type:Journal Article
- Keywords:
Leukemia,myelocytic,acute;
t(8;
21);
AML1-ETO;
Clinic target-treatment
- From:
Journal of Leukemia & Lymphoma
2010;19(6):380-382
- CountryChina
- Language:Chinese
-
Abstract:
One of the sub-types of acute myeloid leukemia(AML) characterized by the translocation of chromosome 8 to chromosome 21 and the expression of AML1-ET0 leukemia genesis fusion gene was proven to have better prognosis. Although remission rate has been improved by the combined chemotherapy primarily containing high dose cytarabine,it seems that target treatment with AML1-ET0 fusion gene/protein should finally cure this disease. In this article,we reviewed the relative studies and clinic target-treatment on AML1-ETO.
